Intellia Therapeutics (NTLA) Tops Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.38), $0.12 better than the analyst estimate of ($1.50). Revenue for the quarter came in at $12 million versus the consensus estimate of $12.45 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- JPMorgan Upgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Neutral
- Kotak Upgrades Shriram Finance Ltd (SHFL:IN) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
